AIRLINK 74.00 Decreased By ▼ -0.25 (-0.34%)
BOP 5.14 Increased By ▲ 0.09 (1.78%)
CNERGY 4.55 Increased By ▲ 0.13 (2.94%)
DFML 37.15 Increased By ▲ 1.31 (3.66%)
DGKC 89.90 Increased By ▲ 1.90 (2.16%)
FCCL 22.40 Increased By ▲ 0.20 (0.9%)
FFBL 33.03 Increased By ▲ 0.31 (0.95%)
FFL 9.75 Decreased By ▼ -0.04 (-0.41%)
GGL 10.75 Decreased By ▼ -0.05 (-0.46%)
HBL 115.50 Decreased By ▼ -0.40 (-0.35%)
HUBC 137.10 Increased By ▲ 1.26 (0.93%)
HUMNL 9.95 Increased By ▲ 0.11 (1.12%)
KEL 4.60 Decreased By ▼ -0.01 (-0.22%)
KOSM 4.83 Increased By ▲ 0.17 (3.65%)
MLCF 39.75 Decreased By ▼ -0.13 (-0.33%)
OGDC 138.20 Increased By ▲ 0.30 (0.22%)
PAEL 27.00 Increased By ▲ 0.57 (2.16%)
PIAA 24.24 Decreased By ▼ -2.04 (-7.76%)
PIBTL 6.74 Decreased By ▼ -0.02 (-0.3%)
PPL 123.62 Increased By ▲ 0.72 (0.59%)
PRL 27.40 Increased By ▲ 0.71 (2.66%)
PTC 13.90 Decreased By ▼ -0.10 (-0.71%)
SEARL 61.75 Increased By ▲ 3.05 (5.2%)
SNGP 70.15 Decreased By ▼ -0.25 (-0.36%)
SSGC 10.52 Increased By ▲ 0.16 (1.54%)
TELE 8.57 Increased By ▲ 0.01 (0.12%)
TPLP 11.10 Decreased By ▼ -0.28 (-2.46%)
TRG 64.02 Decreased By ▼ -0.21 (-0.33%)
UNITY 26.76 Increased By ▲ 0.71 (2.73%)
WTL 1.38 No Change ▼ 0.00 (0%)
BR100 7,874 Increased By 36.2 (0.46%)
BR30 25,596 Increased By 136 (0.53%)
KSE100 75,342 Increased By 411.7 (0.55%)
KSE30 24,214 Increased By 68.6 (0.28%)
Business & Finance

Abbott's new testing kits can detect coronavirus in five minutes

Abbott’s molecular point-of-care test for the detection of novel coronavirus (COVID-19) can deliver a positive resu
Published March 30, 2020
  • Abbott’s molecular point-of-care test for the detection of novel coronavirus (COVID-19) can deliver a positive result in as little as five minutes and negative results in 13 minutes.
  • Currently, the ID NOW COVID-19 test is available only in the US.

The American medical devices and health care company Abbott Laboratories has developed a molecular point-of-care test to detect novel coronavirus, which the company claims can detect the virus in five minutes.

As per the company, the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for Abbott’s molecular point-of-care test for the detection of novel coronavirus (COVID-19), which can deliver a positive result in as little as five minutes and negative results in 13 minutes.

The test will run on the company's ID NOW platform is a small, lightweight about 6.6 pounds and portable about the size of a small toaster and works on molecular technology, and is designed to providing rapid results in a wide range of healthcare settings such as physicians' offices, urgent care clinics, and hospital emergency departments.

"The COVID-19 pandemic will be fought on multiple fronts, and a portable molecular test that offers results in minutes adds to the broad range of diagnostic solutions needed to combat this virus," said Robert B. Ford, president, and chief operating officer, Abbott. "With rapid testing on ID NOW, healthcare providers can perform molecular point-of-care testing outside the traditional four walls of a hospital in outbreak hotspots."

Abbott will be making ID NOW COVID-19 tests available next week to healthcare providers in urgent care settings in the US, where the majority of ID NOW instruments are in use today.

The company informed they will be able to produce about 50,000 ID NOW tests per day. “With the combination of our ID NOW and m2000 COVID-19 testing capabilities, we will supply about 5 million tests per month.”

Currently, the ID NOW COVID-19 test is available only in the US as this is where most of our ID NOW instruments are in use today. “We’re also working on additional testing that we can get to more places around the world including our m2000 test that was approved last week,” the company added.

 

 

Comments

Comments are closed.